Celgene Corporation provided earnings guidance for the full year 2016 and 2017. For the year 2016, total net product sales are expected to be approximately $11,187 million, up 22% year-over-year. GAAP operating margin is expected to be approximately 28%, an increase from 24% in the prior year, primarily due to increased product sales. GAAP diluted EPS is expected to be in the range of $2.43 to $2.51, a 27% year-over-year increase. Adjusted operating margin is expected to be approximately 55% for the full year, an increase of 290 basis points (bps) year-over-year. Adjusted diluted EPS is expected to be approximately $5.94, a 26% year-over-year increase. In 2017, total revenue is expected to be approximately $13.0 billion to $13.4 billion, an 18% increase year-over-year, based on the mid-point of the range. The negative impact of foreign exchange on total revenue is expected to be approximately $170 million in 2017. Based on U.S. Generally Accepted Accounting Principles, diluted earnings per share for the full-year 2017 is expected to be in the range of $5.85 to $6.21, excluding the impact of any strategic transactions, impairments and loss contingencies that have not yet occurred. For the full-year 2017, adjusted diluted EPS is expected to be in the range of $7.10 to $7.25, a 21% increase year-over-year, based on the mid-point of the range.